Product Description
GeneChem is developing GB5005 for the treatment of blood cancers and autoimmune diseases. (Sourced from: https://genechembio.com/pipeline.html)
Mechanisms of Action: CAR-T, CD19
Novel Mechanism: No
Modality: Autologous CAR-T
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GeneChem
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin|T-Cell Lymphoma|Lymphoma, B-Cell
Phase 1: Lupus Erythematosus, Systemic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2000033480 |
ChiCTR2000033480 | N/A |
Recruiting |
Leukemia |
2022-06-04 |
|||
NCT06875063 |
XMDYYYXYK-17 | P1 |
Recruiting |
Lymphoma, B-Cell|T-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2026-05-31 |
2025-03-14 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|